Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Nivolumab for IDH-mutated Gliomas With Hypermutator Phenotype

Next Previous
Trial Profile

A Phase II Trial of Nivolumab for IDH-mutated Gliomas With Hypermutator Phenotype

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Glioma
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Feb 2019 Planned initiation date changed from 15 Feb 2019 to 25 Feb 2019.
    • 08 Feb 2019 Planned initiation date changed from 8 Feb 2019 to 15 Feb 2019.
    • 01 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 8 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top